Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Up 6.3%

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report)'s share price rose 6.3% on Thursday . The company traded as high as $36.92 and last traded at $36.76. Approximately 234,757 shares were traded during trading, a decline of 70% from the average daily volume of 769,783 shares. The stock had previously closed at $34.57.

Analyst Upgrades and Downgrades

TARS has been the subject of a number of analyst reports. Jefferies Financial Group upped their target price on Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the stock a "buy" rating in a report on Wednesday, March 6th. HC Wainwright upped their target price on Tarsus Pharmaceuticals from $50.00 to $57.00 and gave the stock a "buy" rating in a report on Wednesday, February 28th. Oppenheimer reiterated an "outperform" rating and set a $59.00 price objective (up previously from $55.00) on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 28th. The Goldman Sachs Group increased their price objective on Tarsus Pharmaceuticals from $19.00 to $30.00 and gave the company a "neutral" rating in a report on Thursday, February 29th. Finally, Barclays increased their price objective on Tarsus Pharmaceuticals from $40.00 to $50.00 and gave the company an "overweight" rating in a report on Wednesday, February 28th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $48.38.

Tarsus Pharmaceuticals Price Performance

The firm has a 50-day simple moving average of $31.13 and a two-hundred day simple moving average of $22.14. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -7.83 and a beta of 1.07. The company has a current ratio of 6.93, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its earnings results on Tuesday, February 27th. The company reported ($1.31) EPS for the quarter, beating analysts' consensus estimates of ($1.37) by $0.06. The business had revenue of $13.08 million for the quarter, compared to analyst estimates of $4.63 million. During the same quarter last year, the business earned ($0.49) earnings per share. As a group, analysts predict that Tarsus Pharmaceuticals, Inc. will post -4.59 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Seshadri Neervannan sold 4,879 shares of the firm's stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $30.60, for a total transaction of $149,297.40. Following the sale, the chief operating officer now directly owns 64,767 shares in the company, valued at approximately $1,981,870.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, COO Seshadri Neervannan sold 4,879 shares of the firm's stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total value of $149,297.40. Following the transaction, the chief operating officer now directly owns 64,767 shares of the company's stock, valued at approximately $1,981,870.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Bobak R. Azamian sold 10,415 shares of the firm's stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $318,699.00. Following the completion of the transaction, the chief executive officer now directly owns 26,456 shares in the company, valued at $809,553.60. The disclosure for this sale can be found here. Insiders have sold 24,496 shares of company stock worth $749,578 in the last ninety days. Company insiders own 11.54% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of TARS. Deerfield Management Company L.P. Series C purchased a new position in Tarsus Pharmaceuticals in the 3rd quarter worth approximately $13,399,000. BlackRock Inc. raised its position in shares of Tarsus Pharmaceuticals by 51.0% during the 2nd quarter. BlackRock Inc. now owns 2,199,753 shares of the company's stock valued at $39,750,000 after buying an additional 742,493 shares during the period. Artisan Partners Limited Partnership purchased a new stake in shares of Tarsus Pharmaceuticals during the 3rd quarter valued at approximately $7,093,000. RTW Investments LP raised its position in shares of Tarsus Pharmaceuticals by 13.1% during the 3rd quarter. RTW Investments LP now owns 2,880,701 shares of the company's stock valued at $51,190,000 after buying an additional 332,576 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Tarsus Pharmaceuticals by 25.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,551,802 shares of the company's stock valued at $27,576,000 after buying an additional 316,128 shares during the period. 90.01% of the stock is owned by hedge funds and other institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.